The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI).
 
Alexander Andreev-Drakhlin
No Relationships to Disclose
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Ana Cecilia Adriazola
No Relationships to Disclose
 
Leah Shaw
No Relationships to Disclose
 
Lidia Lopez
No Relationships to Disclose
 
Marihella James
No Relationships to Disclose
 
Surena F. Matin
Honoraria - Taris BioMedical; Urogen pharma
Consulting or Advisory Role - C-SATS; Peloton Therapeutics; QED Therapeutics; Taris BioMedical; Urogen pharma
Research Funding - AT&T; Specialized Program in Oncology Research (SPORE)
Travel, Accommodations, Expenses - MSD
 
Omar Alhalabi
No Relationships to Disclose
 
Jianjun Gao
Consulting or Advisory Role - ARMO BioSciences; AstraZeneca; crispr therapeutics; Jounce Therapeutics; Nektar; Pfizer; Polaris
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; EMD Serono; Genentech; Janssen; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen
Research Funding - Basilea; BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Sangeeta Goswami
Research Funding - Dragonfly Therapeutics
 
Lianchun Xiao
No Relationships to Disclose
 
Aradhana M. Venkatesan
Honoraria - Pfizer
Research Funding - Toshiba
Travel, Accommodations, Expenses - Pfizer
 
Matthew T Campbell
Honoraria - Eisai; EMD Serono; Genentech/Roche; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
Research Funding - Exelixis